Permit for Viscaria granted, a major milestone Permit allows for 3.
Redeye updates its view of Egetis following the Q1 report and recent events in the company.
Redeye comments on Tessin’s Q1 results, which showed lower loan volumes than expected, negatively im...
Sales in line, but EBITA +4% vs. ABGSCe Lower opex and better customer intake than expected Expect c...
Redeye leaves a short comment following Lipum’s announcement of a loan commitment of SEK20m with Fle...
Obducat publicerade den 3 maj 2024 bolagets delårsrapport för det första kvartalet 2024, vilken visa...
CapMan’s Q1 clearly beat our estimates driven by carried interest and positive fair value changes, b...
Raute’s Q1 showed how Wood Processing is to return to black after a string of challenging years.
Setanaxib delivers promising results when used together with Keytruda in a tumour type, where Setana...
Sämre än marknadens esitmat… Omsättningen i kvartalet uppgick till 619 mkr, vilket motsvarar en valu...
IRL757 Ph 1 received regulatory approval SAD/MAD study to finish by YE'24 Results expected in Q1'25e...
Redeye provides its initial comments on Catella's Q4 2023 report, which came in moderately below our...
Redeye makes some minor estimate changes following the report (lowering sales from TUBEX in Africa),...
Following the app-integrated offline payments with Digital Cash, and recent expansion with App-Integ...
Calliditas entered 2024 with a strong Tarpeyo patient enrollment.
Ascelia achieved the vital objective to secure a re-reader evaluation of SPARKLE by May 2024.
Redeye states the report was below expecations across the board.
Redeye’s near-term forecasts are now a little lower, following a rather slow run-up to the year.
CapMan's Q1 came in significantly above LSEG Data & Analytics consensus expectations, mostly explain...
MTI Investment SE (”MTI” eller ”Bolaget”) meddelade den 2 maj 2024 att Bolaget har ingått villkorade...
